Huntsworth last week announced the acquisition of two companies to expand its marketing and medical divisions.
According to a press release, Huntsworth bought 85 percent of Kyne for $17.3 million and 70 percent of CC, a market access and health economics and outcomes research consultancy, for $17.2 million. Kyne provides a range of services to biotech and pharmaceutical companies.
“These acquisitions demonstrate Huntsworth’s commitment to supporting the changing needs of pharmaceutical and biotech clients,” Huntsworth CEO Paul Taaffe said in a statement.
To read more, click here.